一项随机、活性对照、评估者设盲试验,旨在确定单剂CERVAVAC®四价HPV疫苗与Gardasil®四价疫苗在赞比亚9至14岁女孩和男孩及15至20岁女孩/女性中免疫原性的非劣效性 (CervALONE)
一项随机、活性对照、评估者设盲试验,旨在评估单剂CERVAVAC®四价HPV疫苗与Gardasil®四价疫苗在赞比亚9至14岁女孩和男孩以及15至20岁女孩/女性中免疫原性的非劣效性
The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly to the boys and girls/women in these age group and they will be followed up to check the immune status developed in them after vaccination. The status of immune response developed by the two differnet vaccines will be compared in these group of participants of the study.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Lusaka、赞比亚
- Chipata and Matero First Level Hospitals
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Girl/woman between 9 and 20 years of age and boy between the age of 9 and 14 years at the time of recruitment.
- Participant willing to sign a written informed consent (for participants 18 years of age and above).
- Parent (s) willing to provide written informed consent and participant is willing to sign written assent form for participation (for participants below 18 years of age at the time of eligibility assessment).
- Participant or parent (s) willing to comply with all study requirements.
- Participants who are determined by Medical History (MH), Physical Examination (PE) and clinical judgment of the Investigator to be eligible for inclusion in the study.
Exclusion Criteria:
- Participants who are sexually active and missed their last menstrual period will have a urine pregnancy test and will be excluded if found pregnant.
- Participant has a known history of prior vaccination with any HPV vaccine.
- Participant known to be HIV positive (no routine HIV testing will be performed unless clinically indicated)
- Participant currently enrolled in any other clinical studies of investigational products.
- Participant with a current diagnosis or prior history of genital warts or treatment of genital warts.
- Participant with a current diagnosis or prior history of cervical intraepithelial neoplasia (CIN) or cervical cancer.
- Participant has a history of any allergic diseases or severe allergic reaction to any agent/vaccine product (e.g., swelling of the mouth and throat, difficulty in breathing, hypotension, or shock).
- Participant has had an acute illness (moderate or severe) and/or fever (body temperature ≥ 38°C or ≥ 100.4 °F) at the time of vaccination or during the 72 hours prior to the vaccination.
- Bleeding diathesis or uncontrolled condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate IM injection.
- Participant has history of major congenital defects or illness that requires medical therapy, as determined by MH or clinical assessment.
- Participant has had chronic administration (defined as more than 14 days) of high doses of corticosteroids (prednisone or equivalent at a dose of >0.5 mg/kg/day), cytotoxic agents or radiotherapy or immunoglobulins, immunosuppressants or other immune-modifying drugs in last 3 months or planned at any time during the study.
- Participant has history of receiving a blood transfusion or other blood products in three months prior to screening.
- Planned administration of a vaccine not foreseen by the study protocol within 14 days before and 14 days after any dose of study vaccine except TT given for emergency use and any vaccine mandated by government program.
- Participant has history of any major pulmonary, cardiovascular, renal, neurological, metabolic, gastro-intestinal, hepato-biliary, hematological functional abnormality, mental or physical disability, blood dyscrasia or any condition which in the opinion of the Investigator might interfere with the evaluation of the study objectives.
- Participant has history of any cancer, organ transplant or any other immune system disease.
- Individuals who, in the opinion of the investigator, are unlikely to be compliant to all study procedures
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Girls/women and boys vaccinated with single dose CERVAVAC-4 vaccine
CERVAVAC-4 single dose vaccine will be administered - off label in one arm |
CERVAVAC-4 single dose vaccine
其他名称:
Gardasil-4 single dose
其他名称:
|
|
有源比较器:Girls/women and boys vaccinated with single dose Gardasil-4 vaccine
Gardasil-4 single dose vaccine will be administered in one arm |
CERVAVAC-4 single dose vaccine
其他名称:
Gardasil-4 single dose
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
通过Meso-scale Discovery (MSD®)平台采用M9ELISA方法检测第24个月采集的血样,评估抗HPV 16和18型IgG抗体的几何平均滴度(GMT)
大体时间:24个月
|
24个月
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.